Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Intrahepatic Cholangiocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Peng Wang, M.D.) · peng_wang@fudan.edu.cn
Contact: Principal Investigator (Peng Wang, M.D.)

Study leads

Peng Wang, MD
Principal Investigator
Fudan University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)

Intrahepatic Cholangiocarcinoma (Icc) · HAIC · Durvalumab

Abroad (travel likely)RecruitingPHASE2

Chengdu, China

Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (Icc)

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma

Advanced Intrahepatic Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Hangzhou, China

Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

Intrahepatic Cholangiocarcinoma (Icc) · Gall Bladder Cancer

Abroad (travel likely)RecruitingPHASE2

Tianjin, China